A total of 141 patients admitted to hospital with a diagnosis of suspected myocardial infarction were randomized to treatment with intravenous diamorphine (71) or nalbuphine (70). Myocardial infarction was subsequently confirmed in 109 patients. Both drugs provided good analgesia. Heart rate, blood pressure, respiratory rate, peak flow and minute volume were measured over a three-hour study period. Except for a slight fall in systolic blood pressure in the nalbuphine-treated group, there were no statistically significant differences between the groups. The nalbuphine-treated group had higher levels of aspartate aminotransferase and hydroxybutyric acid dehydrogenase but not creatine phosphokinase. The haemodynamic outcome and mortality at three months of the two groups were similar. It is concluded that nalbuphine provides effective analgesia coupled with few adverse circulatory or respiratory effects.
Introduction
Pain at the time of myocardial infarction may be so severe as to require the use of opiate analgesics. Diamorphine is frequently chosen for this purpose in the United Kingdom'. Effective analgesia with opiates provides two other beneficial effects: reduction of sympathetic nervous activity, lowering of peripheral vascular resistance and hence cardiac work and myocardial oxygen demand2"3. The proposed introduction of a new agent in this role demands a direct comparison with the established drug. To this end, a prospective, randomized, doubleblind trial of nalbuphine against diamorphine was undertaken to assess level of analgesia, incidence of side effects and circulatory and respiratory effects of the two drugs. During the period of the study, 577 patients were admitted to the coronary care units of the three participating hospitals with a diagnosis of suspected myocardial infarction. Of these, 141 patients (104 males and 37 females) were suspected of having suffered a myocardial infarction as suggested by the history and admission ECG; the diagnosis was subsequently checked by seeking typical evolutionary enzyme and/or ECG changes4'5. Table 1 gives the reasons for non-inclusion in the trial. Patients gave informed consent prior to entry into the trial. Of the 141 patients entering the trial, 109 were subsequently confirmed as having suffered an acute myocardial infarction. Of 130 who completed the study, 99 had suffered a myocardial infarction.
Baseline haemodynamic and respiratory function tests were performed. The patients were then given intravenous nalbuphine (70 patients) or diamorphine (71 patients). Both drugs had been prepared as identical colourless solutions. The two treatment groups did not differ appreciably in sex, age or weight ( Table 2) .
Three ml of a solution containing 10 mg/ml of nalbuphine or 2.5 mg/ml of diamorphine were available for each patient; 20 mg of nalbuphine were considered to be equipotent to 5 mg of diamorphine. The dose administered was decided by the physician in attendance. Most patients received 2 ml, i.e. 5 mg of diamorphine (43 patients) or 20 mg of nalbuphine (45 patients).
On admission to the study measurements were made of heart rate, systolic and diastolic (Korotkoff phase 5) blood pressure, respiratory rate and wherever possible peak flow and minute volume (using a Wright peak flow meter and spirometer). These measurements were repeated at intervals for 180 minutes after administration of the analgesic. The severity of cardiac pain and the presence or absence of side effects were also noted on each occasion. Plasma cardiac enzymescreatine phosphokinase (CPK), aspartate aminotransferase (AST), and hydroxybutyric acid dehydrogenase (HBD) -were measured and twelve lead ECGs recorded on admission and 24 and 48 hours later. After the assessment period, patients were asked to give their opinion of the analgesic efficacy of the trial drug on a 4-point scale (poor, fair, good, excellent). The significances ofdifferences in occurrence rates between treatment groups were tested by chi-squared tests, and differences in quantitative parameters were tested by analysis of variance or Wilcoxon rank sum tests.
Results
Myocardial infarction was confirmed in 51 of the 71 patients who received diamorphine and 58 of the 70 who received nalbuphine. The remaining patients were deemed to have severe angina at rest: their history was indicative of ischaemic pain but either the ECG or enzyme changes were insufficient to sustain a diagnosis of infarction. Both drugs provided good analgesia: 36 (51%) of the patients treated with diamorphine and 38 (54%) of those treated with nalbuphine received good or excellent analgesia. Overall there was no significant difference in the efficacy of the two drugs.
Eleven patients did not complete the study: 7 were withdrawn and 4 (discussed below) died. Six patients, one who had received diamorphine and 5 who had received nalbuphine, were withdrawn from the study because of the need for additional analgesia. One patient, who had received diamorphine, was withdrawn from the study because ofapnoeic attacks considered to be due to the opiate. The overall incidence of side effects among patients completing the study was 42% (28/67) in the diamorphine group compared with 35% (22/63) in the nalbuphine-treated group. The differences are not quite significant at the 5% level, using a one-tailed test. Dizziness or nausea were experienced by 21 (31%) patients who had received diamorphine and 15 (24%) who had been given nalbuphine. Other minor side effects such as sweating or headache occurred in 8 (12%) of the former group and 6 (10%) of the latter. None of these patients had to be withdrawn from the study.
Haemodynamically, both groups were stable. There were slight falls in both pulse rate and blood pressure following admission to the study (Figures 1  and 2) . Except for the slight fall in systolic blood pressure in the nalbuphine-treated group (P<0.05), the differences between the groups did not reach significance at the 5% level. Respiratory function was also stable. Respiratory rate and tidal volume are plotted in Figure 3 . By chance, tidal volume of the patients who subsequently received diamorphine was substantially higher on admission to the study. Analysis of subsequent changes showed no significant differences between the groups.
The enzyme rises tended to be higher in patients given nalbuphine than in those given diamorphine ( Table 3 ). The statistical analysis ofthe enzyme levels is complicated by the presence ofdifferences between the normal ranges of the three participating hospitals. Consequently, a detailed statistical analysis was carried out on these data, taking into account the hospital and also other relevant factors such as the site of the infarct and the use of concomitant medication including beta-blockers. The conclusion from this analysis was that the difference is statistically significant for AST (P<0.001) and HBD (P<0.05), but not for CPK (this enzyme was only measured at one hospital). The clinical significance ofthis finding Figure 3 . A, respiratory rates (breaths/min) and B, tidal volume (ml) following diamorphine or nalbuphine. Differences between groups are not significant. Bars indicate one standard error of the difference between means --- Four patients died during the study; 2 had received diamorphine and 2 nalbuphine. They all deteriorated rapidly and died of cardiogenic shock, myocardial rupture or ventricular fibrillation. In none of these cases could death be attributed to the administration of analgesia. After the end of the study a further 2 patients who had been given diamorphine and one who had received nalbuphine died in the next 69 hours. Three months after the trial a total of 7 (10%) of the former group and 10 (14%) of the latter were known to have died.
Discussion
Nalbuphine is an opioid analgesic related to both oxymorphone and naloxone. Although it has been compared-with morphine and found to be rather less than equipotent in producing analgesia, no direct comparisons with diamorphine have been made69. A more recent study suggested that nalbuphine has half the analgesic potency of morphine on a mg for mg basis10. In the present study, the mg dosage of nalbuphine was four times that of diamorphine.
The studies mentioned above have demonstrated the safety of nalbuphine in postoperative adult patients6 8 and children following circumcision9 as well as in a mixed group of medical and surgical patients7. Other studies have illustrated its use in anaesthesia'1 and premedication"2. Nalbuphine has an equivalent depressant effect on respiration compared with morphine when both are given in a dose of 10mg to a 70kg man'3-14. However, unlike morphine, doses above 30 mg do not produce further respiratory depression'3; such depression as is produced is antagonized by 0.4 mg of naloxone.
Provision of adequate and safe analgesia is an essential part of the management of acute myocardial infarction. In addition to causing patient distress, severe pain is often accompanied by physiological changes which may prove dangerous. Levels of catecholamines are very elevated, often leading to tachycardia and, in some cases, systemic hypertension. Myocardial oxygen demand is thus increased at a time when coronary blood flow is, of necessity, limited2 3. This combination of circumstances seems to be the substrate leading to the occurrence of potentially fatal arrhythmias such as ventricular tachycardia or fibrillation. The administration of opiates leads to an amelioration of this situation and may thus play a role in maintaining haemodynamic stability in these patients. Before a direct comparison of a new opiate such as nalbuphine can be undertaken in patients with acute infarction, a degree of haemodynamic safety in less ill patients must have been demonstrated.
Nalbuphine has been injected into the pulmonary arteries of patients with coronary artery disease undergoing cardiac catheterization. Following the administration of 10 mg of nalbuphine, there were no significant changes in haemodynamics over a period of 20 minutes'5. Similarly, there were no deleterious effects recorded in a group of patients given intravenous nalbuphine (10mg) within 72 hours of an acute myocardial infarction'6; however; these patients did not have cardiac pain at the time of drug administration. No adverse haemodynamic effects were-noted in patients given up to 2-3 mg/kg nalbuphine during coronary artery bypass operations 7.
These findings are in marked contrast to the unfavourable haemodynamic changes which may occur in patients given pentazocine '8 -20. Although in the present study there appeared to be a greater rise in enzyme levels in patients who received nalbuphine, this did not lead to a less favourable outcome as judged by haemodynamic deterioration or survival at three months. There was no direct evidence that this rise of HBD and AST was due to increased cardiac muscle necrosis in the nalbuphine group. Indeed, the differences in CPK levels between the two treatment groups did not reach statistical significance.
This study extends the previous evidence indicating that nalbuphine causes little haemodynamic or respiratory disturbance when given to patients with severe ischaemia cardiac pain due to myocardial infarction or angina. Nalbuphine thus offers an alternative to diamorphine in these circumstances. Unlike diamorphine it is not a controlled drug. This is ofgreat practical importance in the development of mobile resuscitation teams and may facilitate the administration of adequate analgesia by paramedical staff.
